Annals of neurology
-
Annals of neurology · Aug 2011
Measurement of intraocular and intracranial pressure: is there a relationship?
To study whether noninvasive, intraocular pressure (IOP) measurements significantly correlate with standard intracranial pressure (ICP) measurements. ⋯ No significant relationship between ICP and IOP was observed. Noninvasive IOP measurements do not predict ICP.
-
To investigate whether inhibition of mitochondrial p53 association using pifithrin-μ (PFT-μ) represents a potential novel neuroprotective strategy to combat perinatal hypoxic-ischemic (HI) brain damage. ⋯ We are the first to show that prevention of mitochondrial p53 association by PFT-μ strongly improves functional outcome and decreases lesion size after neonatal HI. PFT-μ not only inhibits mitochondrial release of cytochrome c, but also inhibits oxidative stress. We propose that as a consequence nuclear accumulation of p53 and transcription of proapoptotic target genes are prevented. In conclusion, targeting p53 mitochondrial association by PFT-μ may develop into a novel and powerful neuroprotective strategy.
-
The aim of this study was to compare children and young adults with acute ischemic stroke (AIS) in 2 large registries. ⋯ Although stroke etiology and risk factors in children and young adults are different, stroke severity and clinical outcome were similar in both groups.
-
Annals of neurology · Jul 2011
Comparative StudyXenon augmented hypothermia reduces early lactate/N-acetylaspartate and cell death in perinatal asphyxia.
Additional treatments for therapeutic hypothermia are required to maximize neuroprotection for perinatal asphyxial encephalopathy. We assessed neuroprotective effects of combining inhaled xenon with therapeutic hypothermia after transient cerebral hypoxia-ischemia in a piglet model of perinatal asphyxia using magnetic resonance spectroscopy (MRS) biomarkers supported by immunohistochemistry. ⋯ Compared with no treatment, xenon-augmented hypothermia reduced cerebral MRS abnormalities and cell death markers in some brain regions. Compared with hypothermia, xenon-augmented hypothermia did not reach statistical significance for any measure. The safety and possible improved efficacy support phase II trials.